The United States market has shown robust performance recently, with a 1.2% increase over the past week and a substantial 29% rise over the last year, while earnings are projected to grow by 17% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on current technological trends but also demonstrate strong potential for sustained revenue and earnings growth.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| AppLovin | 21.01% | 21.71% | ★★★★★★ |
| Sandisk | 39.74% | 40.96% | ★★★★★★ |
| 21.88% | 25.36% | ★★★★★★ | |
| Krystal Biotech | 29.09% | 36.48% | ★★★★★★ |
| Palantir Technologies | 30.22% | 31.80% | ★★★★★★ |
| Fabrinet | 21.38% | 23.34% | ★★★★★★ |
| Marker Therapeutics | 64.28% | 69.04% | ★★★★★★ |
| Gorilla Technology Group | 54.35% | 96.69% | ★★★★★☆ |
| KVH Industries | 28.67% | 146.09% | ★★★★★☆ |
| Zscaler | 15.84% | 49.86% | ★★★★★☆ |
Click here to see the full list of 70 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Clearfield (CLFD)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Clearfield, Inc. designs, manufactures, and distributes fiber management, protection, and delivery products globally with a market cap of $594.27 million.
Operations: The company generates revenue primarily from its fiber management, protection, and delivery product offerings, amounting to $148.55 million.
Despite a challenging year with a 31.8% drop in earnings, Clearfield is poised for significant recovery, forecasting an impressive 100.8% annual earnings growth over the next three years, outpacing the US market's 16.8%. This growth trajectory is bolstered by strategic partnerships, like the recent one with VoltServer to enhance 5G infrastructure, showcasing its commitment to innovation and market expansion. Additionally, Clearfield's proactive approach in share repurchases—buying back shares worth $68.98 million—reflects confidence in its financial strategy and future prospects. With these moves, Clearfield aims to strengthen its position in high-tech solutions for telecommunications and data centers, navigating past short-term setbacks towards sustainable growth.
- Delve into the full analysis health report here for a deeper understanding of Clearfield.
Examine Clearfield's past performance report to understand how it has performed in the past.
Agilysys (AGYS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Agilysys, Inc. is a company that develops and markets software-enabled solutions and services for the hospitality industry across North America, Europe, the Asia-Pacific, and India, with a market cap of $2.24 billion.
Operations: Agilysys focuses on delivering software solutions to the global hospitality industry, generating $319.31 million in revenue. The company's operations span North America, Europe, the Asia-Pacific, and India.
Agilysys, with its recent unveiling of over 30 AI-powered features at the INSPIRE Technology User Conference, is steering the hospitality technology sector towards more personalized and efficient operations. These innovations, expected to enhance guest experiences significantly, are part of a strategic move to embed AI across its product suite. Financially, Agilysys is on a robust path with a year-over-year revenue jump to $319.31 million and net income soaring to $38.79 million from $23.23 million last year. The company's forward-looking guidance anticipates revenues reaching up to $370 million in Fiscal 2027, underpinned by at least 30% growth in subscription revenues, showcasing its strong foothold in the evolving tech landscape for hospitality solutions.
Kiniksa Pharmaceuticals International (KNSA)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing medical therapies across the United States, the United Kingdom, and internationally, with a market capitalization of approximately $4.10 billion.
Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, amounting to $754.05 million. The company operates within the biopharmaceutical sector, focusing on medical therapies in multiple regions including the U.S. and U.K.
Kiniksa Pharmaceuticals International, demonstrating robust growth, reported a significant revenue increase to $214.27 million in Q1 2026 from $137.79 million the previous year, reflecting a 14.5% annual growth rate. This performance is bolstered by an impressive earnings jump, with net income rising to $22.59 million from $8.54 million year-over-year and projected revenue for 2026 between $930 million and $945 million, up from earlier forecasts of $900 to $920 million. The company's strategic focus is evident in its R&D commitment, crucial for sustaining innovation and competitiveness in the biotech sector; however, specific R&D expenditure figures were not disclosed in the provided data.
Key Takeaways
- Discover the full array of 70 US High Growth Tech and AI Stocks right here.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com